Thrombophilia due to thrombin defect

Summary

Thrombophilia due to thrombin defect (MONDO:0008559) is a disease caused by F2 (GenCC Definitive), with 5 cohort genes and 549 clinical trials. Top therapeutic interventions include enoxaparin sodium, fondaparinux, and dabigatran etexilate.

At a glance

• Causal gene: F2 (GenCC Definitive)
• Cohort genes: 5
• ClinVar variants: 303
• Clinical trials: 549

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	thrombophilia due to thrombin defect
Mondo ID	MONDO:0008559
OMIM	188050
DOID	DOID:0080701, DOID:0111907
SNOMED CT	111293003
UMLS	C3160733
MedGen	463623
GARD	0010815
Is cancer (heuristic)	no

Also known as: factor II-related thrombophilia · hyperprothrombinemia · prothrombin 20210G>A thrombophilia · prothrombin G20210A thrombophilia · prothrombin thrombophilia · prothrombin-related thrombophilia · THPH1 · thrombophilia 1 due to thrombin defect · thrombophilia due to thrombin defect · Venous thromboembolism · venous thromboembolism, susceptibility to · venous thrombosis, protection against

Data availability: 303 ClinVar variants · 4 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by body system or component › hematologic disorder › blood coagulation disease › thrombophilia › inherited thrombophilia › thrombophilia due to thrombin defect

Related subtypes (11): factor 5 excess with spontaneous thrombosis, thrombophilia due to activated protein C resistance, thrombophilia, X-linked, due to factor 9 defect, thrombophilia, familial, due to decreased release of tissue plasminogen activator, heparin cofactor 2 deficiency, hereditary thrombophilia due to congenital histidine-rich (poly-L) glycoprotein deficiency, hereditary antithrombin deficiency, thrombomodulin-related bleeding disorder, hereditary thrombophilia due to congenital protein S deficiency, hereditary thrombophilia due to congenital protein C deficiency, thrombophilia, X-linked, due to factor 8 defect

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

303 retrieved; paginated sample, class counts are floors:

112 uncertain significance, 99 conflicting classifications of pathogenicity, 49 benign/likely benign, 13 pathogenic/likely pathogenic, 10 benign, 6 pathogenic, 5 likely pathogenic, 5 likely benign, 1 conflicting classifications of pathogenicity; risk factor, 1 pathogenic/likely pathogenic/pathogenic, low penetrance/established risk allele; risk factor, 1 drug response, 1 benign/likely benign; other

ClinVar	Variant (HGVS)	Gene	Classification	Review
29694	NM_000129.4(F13A1):c.603_606del (p.Arg202fs)	F13A1	Pathogenic	criteria provided, single submitter
3594056	NM_000129.4(F13A1):c.523C>T (p.Arg175Ter)	F13A1	Pathogenic	criteria provided, single submitter
13303	NM_000506.3(F2):c.940C>T (p.Arg314Cys)	F2	Pathogenic	criteria provided, single submitter
13310	NM_000506.5(F2):c.*97G>A	F2	Pathogenic/Likely pathogenic/Pathogenic, low penetrance/Established risk allele; risk factor	criteria provided, multiple submitters, no conflicts
2706763	NM_000506.5(F2):c.1499G>A (p.Arg500Gln)	F2	Pathogenic	criteria provided, multiple submitters, no conflicts
31922	NM_000506.5(F2):c.1787G>T (p.Arg596Leu)	F2	Pathogenic	no assertion criteria provided
692073	NM_000506.5(F2):c.1787G>A (p.Arg596Gln)	F2	Pathogenic	criteria provided, multiple submitters, no conflicts
1024006	NM_005957.5(MTHFR):c.1228_1242del (p.Ser410_Lys414del)	MTHFR	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
187869	NM_005957.5(MTHFR):c.202C>G (p.Arg68Gly)	MTHFR	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
187876	NM_005957.5(MTHFR):c.548G>A (p.Arg183Gln)	MTHFR	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
187893	NM_005957.5(MTHFR):c.1320G>A (p.Ser440=)	MTHFR	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
187897	NM_005957.5(MTHFR):c.1632+2T>G	MTHFR	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
3519	NM_005957.5(MTHFR):c.470G>A (p.Arg157Gln)	MTHFR	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
3529	NM_005957.5(MTHFR):c.968T>C (p.Leu323Pro)	MTHFR	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
570071	NM_005957.5(MTHFR):c.155G>A (p.Arg52Gln)	MTHFR	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
654511	NM_005957.5(MTHFR):c.1130G>A (p.Arg377His)	MTHFR	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
660609	NM_005957.5(MTHFR):c.1699C>T (p.Arg567Ter)	MTHFR	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
800827	NM_005957.5(MTHFR):c.680C>T (p.Thr227Met)	MTHFR	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
848996	NM_005957.5(MTHFR):c.1541_1542del (p.Glu514fs)	MTHFR	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
996033	NM_005957.5(MTHFR):c.459C>G (p.Ile153Met)	MTHFR	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
3599612	NM_000506.5(F2):c.317-1G>A	F2	Likely pathogenic	criteria provided, single submitter
1098292	NM_005957.5(MTHFR):c.1316T>C (p.Leu439Pro)	MTHFR	Likely pathogenic	criteria provided, multiple submitters, no conflicts
222892	NM_005957.5(MTHFR):c.236+1G>A	MTHFR	Likely pathogenic	criteria provided, single submitter
3382551	NM_005957.5(MTHFR):c.1429C>T (p.Gln477Ter)	MTHFR	Likely pathogenic	criteria provided, single submitter
3576271	NM_005957.5(MTHFR):c.727T>G (p.Cys243Gly)	MTHFR	Likely pathogenic	criteria provided, single submitter
3520	NM_005957.5(MTHFR):c.665C>T (p.Ala222Val)	MTHFR	drug response	reviewed by expert panel
911739	NM_000129.4(F13A1):c.1184C>T (p.Ala395Val)	F13A1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
13302	NM_000506.3(F2):c.598G>A (p.Glu200Lys)	F2	Conflicting classifications of pathogenicity; risk factor	criteria provided, conflicting classifications
1676733	NM_000506.5(F2):c.1298+19G>A	F2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
256313	NM_000506.5(F2):c.1602G>A (p.Pro534=)	F2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 8 · Orphanet: 13 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
F2	Definitive	Autosomal dominant	thrombophilia due to thrombin defect	8

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
F2	Orphanet:325	Congenital factor II deficiency
F2	Orphanet:329217	Cerebral sinovenous thrombosis
F13A1	Orphanet:331	Congenital factor XIII deficiency
F5	Orphanet:131	Budd-Chiari syndrome
F5	Orphanet:326	Congenital factor V deficiency
F5	Orphanet:329217	Cerebral sinovenous thrombosis
F5	Orphanet:391320	East Texas bleeding disorder
F5	Orphanet:599579	Factor V Amsterdam bleeding disorder
F5	Orphanet:600194	Factor V Atlanta bleeding disorder
HABP2	Orphanet:319487	Familial papillary or follicular thyroid carcinoma
MTHFR	Orphanet:395	Homocystinuria due to methylene tetrahydrofolate reductase deficiency
MTHFR	Orphanet:563609	Isolated anencephaly
MTHFR	Orphanet:563612	Isolated exencephaly

Cohort genes → proteins

5 cohort genes, 5 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	5

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
F2	HGNC:3535	ENSG00000180210	P00734	Prothrombin	gencc,clinvar
F13A1	HGNC:3531	ENSG00000124491	P00488	Coagulation factor XIII A chain	clinvar
F5	HGNC:3542	ENSG00000198734	P12259	Coagulation factor V	clinvar
HABP2	HGNC:4798	ENSG00000148702	Q14520	Factor VII-activating protease	clinvar
MTHFR	HGNC:7436	ENSG00000177000	P42898	Methylenetetrahydrofolate reductase (NADPH)	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
F2	Prothrombin	Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C.
F13A1	Coagulation factor XIII A chain	Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl-epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibrin clot.
F5	Coagulation factor V	Central regulator of hemostasis.
HABP2	Factor VII-activating protease	Cleaves the alpha-chain at multiple sites and the beta-chain between ‘Lys-53’ and ‘Lys-54’ but not the gamma-chain of fibrinogen and therefore does not initiate the formation of the fibrin clot and does not cause the fibrinolysis directly.
MTHFR	Methylenetetrahydrofolate reductase (NADPH)	Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a cosubstrate for homocysteine remethylation to methionine.

Protein-family classification

Druggable: 4 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.8

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Protease	2	14.7×	0.028
Antibody/Immunoglobulin	1	5.8×	0.320
Enzyme (other)	1	2.4×	0.471
Other/Unknown	1	0.4×	0.983

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
F2	Protease	yes	3.4.21.5	Kringle, GLA_domain, Trypsin_dom
F13A1	Antibody/Immunoglobulin	yes	2.3.2.13	Transglutaminase_N, Transglutaminase-like, Transglutaminase_C
F5	Other/Unknown	no		FA58C, Cupredoxin, Galactose-bd-like_sf
HABP2	Protease	yes	3.4.21.B1	Kringle, EGF, Trypsin_dom
MTHFR	Enzyme (other)	yes	1.5.1.20	Mehydrof_redctse-like, Fadh2_euk, FAD-linked_oxidoreductase-like

Expression context

Cohort genes with no expression data: 0.

5 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	5
unknown	0

Top tissues across cohort

Tissue	Cohort genes
liver	3
right lobe of liver	3
male germ line stem cell (sensu Vertebrata) in testis	1
monocyte	1
mononuclear cell	1
pericardium	1
choroid plexus epithelium	1
pancreatic ductal cell	1
apex of heart	1
corpus epididymis	1
sural nerve	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
F2	117	tissue_specific	marker	right lobe of liver, liver, male germ line stem cell (sensu Vertebrata) in testis
F13A1	261	broad	marker	monocyte, mononuclear cell, pericardium
F5	206	broad	marker	right lobe of liver, liver, choroid plexus epithelium
HABP2	115	tissue_specific	marker	right lobe of liver, pancreatic ductal cell, liver
MTHFR	254	ubiquitous	marker	corpus epididymis, sural nerve, apex of heart

Protein interactions among cohort

Intra-cohort edges: 4.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
HABP2	4,008
MTHFR	3,492
F2	2,709
F13A1	2,346
F5	1,754

Intra-cohort edges

A	B	Sources
F13A1	F2	string_interaction
F2	F5	biogrid_interaction, string_interaction
F2	MTHFR	string_interaction
F5	MTHFR	string_interaction

Structural data

PDB: 4 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
F2	P00734	475
F5	P12259	18
F13A1	P00488	15
MTHFR	P42898	4

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
HABP2	Q14520	77.58

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 49. Enrichment computed across 5 evidence-associated genes (4 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Fibrin formation	2	439.2×	3e-04	F2, F13A1
Amplification and propagation of coagulation cascade	2	317.2×	3e-04	F2, F5
Initiation of coagulation cascade	2	237.9×	4e-04	F2, F5
Regulation of clotting cascade	2	116.5×	0.001	F2, F5
Gamma-carboxylation, transport, and amino-terminal cleavage of proteins	1	2855.0×	0.003	F2
Defective factor VIII causes hemophilia A	1	2855.0×	0.003	F2
R-HSA-9651496	1	951.7×	0.004	F2
Defective F8 cleavage by thrombin	1	951.7×	0.004	F2
Defective cleavage of FV variant at a.a.534	1	951.7×	0.004	F5
Defective cleavage of FV variant at R334	1	951.7×	0.004	F5
Platelet degranulation	2	43.9×	0.004	F13A1, F5
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	2	43.3×	0.004	F2, F5
R-HSA-140875	1	713.8×	0.005	F2
Defective factor XII causes hereditary angioedema	1	713.8×	0.005	F2
Diseases of hemostasis	1	713.8×	0.005	F2
R-HSA-140837	1	356.9×	0.009	F2
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus	1	317.2×	0.009	F2
Gamma-carboxylation of protein precursors	1	285.5×	0.009	F2
Removal of aminoterminal propeptides from gamma-carboxylated proteins	1	285.5×	0.009	F2
R-HSA-140877	1	237.9×	0.010	F2
Complement cascade	1	158.6×	0.014	F2
Metabolism of folate and pterines	1	158.6×	0.014	MTHFR
Platelet Aggregation (Plug Formation)	1	109.8×	0.019	F2
Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation	1	105.7×	0.019	F2
Thrombin signalling through proteinase activated receptors (PARs)	1	89.2×	0.022	F2
Cargo concentration in the ER	1	84.0×	0.022	F5
Regulation of Complement cascade	1	58.3×	0.031	F2
Metabolism of water-soluble vitamins and cofactors	1	45.3×	0.038	MTHFR
COPII-mediated vesicle transport	1	40.8×	0.041	F5
Metabolism of vitamins and cofactors	1	29.1×	0.055	MTHFR

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
blood coagulation, fibrin clot formation	2	674.1×	8e-05	F2, F13A1
blood coagulation	3	104.2×	8e-05	F2, F13A1, F5
response to vitamin B2	1	1685.2×	0.008	MTHFR
response to vitamin K	1	1123.5×	0.008	F5
S-adenosylmethionine metabolic process	1	1123.5×	0.008	MTHFR
obsolete methionine biosynthetic process	1	674.1×	0.008	MTHFR
neutrophil-mediated killing of gram-negative bacterium	1	674.1×	0.008	F2
L-methionine metabolic process	1	561.7×	0.008	MTHFR
response to folic acid	1	481.5×	0.008	MTHFR
thrombin-activated receptor signaling pathway	1	481.5×	0.008	F2
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway	1	481.5×	0.008	F2
obsolete cytolysis by host of symbiont cells	1	421.3×	0.008	F2
negative regulation of platelet activation	1	374.5×	0.008	F2
regulation of blood coagulation	1	374.5×	0.008	F2
homocysteine metabolic process	1	374.5×	0.008	MTHFR
ligand-gated ion channel signaling pathway	1	374.5×	0.008	F2
tetrahydrofolate interconversion	1	337.0×	0.009	MTHFR
negative regulation of astrocyte differentiation	1	306.4×	0.009	F2
peptide cross-linking	1	280.9×	0.009	F13A1
negative regulation of fibrinolysis	1	280.9×	0.009	F2
heterochromatin organization	1	259.3×	0.009	MTHFR
negative regulation of blood coagulation	1	240.7×	0.009	F2
positive regulation of blood coagulation	1	224.7×	0.010	F2
response to amino acid	1	198.3×	0.010	MTHFR
fibrinolysis	1	168.5×	0.012	F2
negative regulation of proteolysis	1	134.8×	0.014	F2
positive regulation of collagen biosynthetic process	1	129.6×	0.014	F2
proteolysis	2	13.7×	0.014	F2, HABP2
blood circulation	1	102.1×	0.016	F5
response to interleukin-1	1	102.1×	0.016	MTHFR

Therapeutics

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 3 · Phased (≥1): 3 · Undrugged: 2

Druggability breadth: 4 of 5 evidence-associated genes (80%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
F2	INDIGOTINDISULFONATE
F5	EDOXABAN

Top cohort targets by molecule count

Symbol	Molecules	Max phase
F2	48	4
F5	2	4
F13A1	1	3
HABP2	0	0
MTHFR	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
INDIGOTINDISULFONATE	4	F2
ARGATROBAN	4	F2
BENZOYL PEROXIDE	4	F2
SUCCIMER	4	F2
EDOXABAN	4	F2, F5
METHYLPREDNISOLONE ACETATE	4	F2
LIOTHYRONINE	4	F2
CAPTOPRIL	4	F2
RIVAROXABAN	4	F2
TELOTRISTAT	4	F2
LUSUTROMBOPAG	4	F2
APIXABAN	4	F2
HEXAMIDINE	4	F2
MELAGATRAN	4	F2
CIANIDANOL	4	F2
BORTEZOMIB	4	F2
DEQUALINIUM	4	F2
SULFAGUANIDINE	4	F2
BETRIXABAN	4	F2
XIMELAGATRAN	4	F2
BIVALIRUDIN	4	F2
DABIGATRAN ETEXILATE	4	F2
PENTAMIDINE	4	F2
GENTIAN VIOLET	4	F2
NAFAMOSTAT	3	F2
MILVEXIAN	3	F2
DABIGATRAN	3	F2
QUERCETIN	3	F2
CAMOSTAT	3	F2
CAMOSTAT MESILATE	3	F2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 4.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
F2	1,269	Binding:1216, Functional:38, ADMET:13, Toxicity:2
F13A1	42	Binding:42
F5	10	Binding:10
HABP2	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
F2	3.4.21.5	thrombin
F13A1	2.3.2.13	protein-glutamine gamma-glutamyltransferase
HABP2	3.4.21.B1
MTHFR	1.5.1.20, 1.5.1.53	methylenetetrahydrofolate reductase [NAD(P)H], methylenetetrahydrofolate reductase (NADPH)

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
F2	1,269

Pharmacogenomics

Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

23 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
INDIGOTINDISULFONATE	4	F2
BENZOYL PEROXIDE	4	F2
SUCCIMER	4	F2
METHYLPREDNISOLONE ACETATE	4	F2
LIOTHYRONINE	4	F2
CAPTOPRIL	4	F2
TELOTRISTAT	4	F2
LUSUTROMBOPAG	4	F2
HEXAMIDINE	4	F2
MELAGATRAN	4	F2
CIANIDANOL	4	F2
BORTEZOMIB	4	F2
DEQUALINIUM	4	F2
SULFAGUANIDINE	4	F2
XIMELAGATRAN	4	F2
BIVALIRUDIN	4	F2
PENTAMIDINE	4	F2
GENTIAN VIOLET	4	F2
NAFAMOSTAT	3	F2
MILVEXIAN	3	F2
QUERCETIN	3	F2
CAMOSTAT	3	F2
CAMOSTAT MESILATE	3	F2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	F2, F5
B	Phased (≥1) drug, not yet approved	1	F13A1
C	Druggable family + PDB, no drug	1	MTHFR
D	Druggable family + AlphaFold only, no drug	1	HABP2
E	Difficult family or no structure, no drug	0

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
MTHFR	0	F2
HABP2	1	—

Clinical trials & evidence

Clinical trials

Clinical trials: 549.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	315
PHASE3	93
PHASE4	54
PHASE2	54
PHASE2/PHASE3	12
PHASE1	11
EARLY_PHASE1	8
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03244020	PHASE4	ENROLLING_BY_INVITATION	LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
NCT04263038	PHASE4	RECRUITING	Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
NCT05735639	PHASE4	RECRUITING	THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
NCT06452342	PHASE4	NOT_YET_RECRUITING	TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study
NCT06523959	PHASE4	RECRUITING	Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial
NCT06581965	PHASE4	RECRUITING	inDividual, Targeted thrombosIS Prophylaxis Versus the Standard ‘One Size Fits All’ Approach in Patients Undergoing Total hIp or Total kNee replaCemenT
NCT06603870	PHASE4	RECRUITING	Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
NCT06845423	PHASE4	RECRUITING	Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk
NCT06958588	PHASE4	RECRUITING	Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis
NCT07189897	PHASE4	RECRUITING	Apixaban or Enoxaparin After Head and Neck Cancer Surgery
NCT07303816	PHASE4	NOT_YET_RECRUITING	Statins to Prevent Cancer Associated Blood Clots
NCT00077753	PHASE4	COMPLETED	EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
NCT00196118	PHASE4	COMPLETED	Study of IVC Filter Retrieval With the Günther Tulip Vena Cava Filter
NCT00437697	PHASE4	TERMINATED	Thromboprophylaxis in Critically Ill Patients
NCT00445328	PHASE4	TERMINATED	Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
NCT00689520	PHASE4	COMPLETED	Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis
NCT00851864	PHASE4	COMPLETED	Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing
NCT00966277	PHASE4	COMPLETED	Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
NCT00967304	PHASE4	COMPLETED	Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism
NCT01119261	PHASE4	COMPLETED	EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol
NCT01119274	PHASE4	COMPLETED	EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon
NCT01119300	PHASE4	COMPLETED	EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin
NCT01210755	PHASE4	COMPLETED	Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
NCT01304108	PHASE4	COMPLETED	Improving Venous Thromboembolism Prophylaxis
NCT01467583	PHASE4	COMPLETED	Fondaparinux in Critically Ill Patients With Renal Failure
NCT01916707	PHASE4	UNKNOWN	Weight Based Enoxaparin in Trauma Patients
NCT02095509	PHASE4	COMPLETED	Pharmacokinetics of Enoxaparin in Intensive Care Patients
NCT02396732	PHASE4	TERMINATED	Aspirin and Enoxaparin for VTE in Trauma
NCT02412982	PHASE4	COMPLETED	Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients
NCT02464969	PHASE4	COMPLETED	Apixaban for the Acute Treatment of Venous Thromboembolism in Children
NCT02474212	PHASE4	COMPLETED	: Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery
NCT02559856	PHASE4	COMPLETED	Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study
NCT02856295	PHASE4	COMPLETED	anti10a Levels in Women Treated With LMWH in the Postpartum Period
NCT02945280	PHASE4	TERMINATED	Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis
NCT02958969	PHASE4	COMPLETED	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
NCT03006562	PHASE4	TERMINATED	PREvention of VENous ThromboEmbolism Following Radical Prostatectomy
NCT03158792	PHASE4	COMPLETED	Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function
NCT03196349	PHASE4	TERMINATED	Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism
NCT03266783	PHASE4	COMPLETED	Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
NCT03426982	PHASE4	UNKNOWN	Comparision Between Activated Partial Thromboplastin Time Versus Anti-Xa Activity in Heparin Monitoring

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ENOXAPARIN SODIUM	4	62
FONDAPARINUX	4	29
DABIGATRAN ETEXILATE	4	21
APIXABAN	4	19
DALTEPARIN SODIUM	4	17
RIVAROXABAN	4	16
EDOXABAN	4	14
WARFARIN	4	6
NADROPARIN CALCIUM	4	4
HEPARIN	4	3
TINZAPARIN SODIUM	4	3
ACENOCOUMAROL	4	2
ARGATROBAN	4	1
BETRIXABAN	4	1
CLARITHROMYCIN	4	1
PHENPROCOUMON	4	1
DABIGATRAN	3	8
SEMULOPARIN SODIUM	3	8
DAREXABAN	3	7
TINZAPARIN	3	5
ABELACIMAB	3	2
BEMIPARIN	3	2
SULODEXIDE	3	1
ANTI-PSGL-1 ANTIBODY SELK2	2	1
GW813893	2	1
LETAXABAN	2	1
ODIPARCIL	2	1
SR-123781A	2	1
ONO-7684	1	1
ENOXAPARIN	0	23